» Articles » PMID: 39609084

Mutation-Driven Immune Microenvironments in Non-Small Cell Lung Cancer: Unrevealing Patterns Through Cluster Analysis

Abstract

Purpose: We aimed to comprehensively analyze the immune cell and stromal components of tumor microenvironment at the single-cell level and identify tumor heterogeneity among the major top-derived oncogene mutations in non-small cell lung cancer (NSCLC) using single-cell RNA sequencing (scRNA-seq) data.

Materials And Methods: The scRNA-seq dataset utilized in this study comprised 64369 primary tumor tissue cells from 21 NSCLC patients, focusing on mutations in , , , , , and the wild-type.

Results: Tumor immune microenvironment (TIM) analysis revealed differential immune responses across NSCLC mutation subtypes. TIM analysis revealed different immune responses across the mutation subtypes. Two mutation clusters emerged: , , and + mutations (MC1); and , , and mutations (MC2). MC1 showed higher tertiary lymphoid structures signature scores and enriched populations of C2-T-IL7R, C3-T/NK-CXCL4, C9-T/NK-NKG, and C1-B-MS4A1 clusters than cluster 2. Conversely, MC2 cells exhibited higher expression levels of , , and chemokines linked to alternative immune pathways. Remarkably, co-occurring and mutations were grouped as MC1. + mutations showed upregulation of peptide synthesis and higher synthetic processes, as well as differences in myeloid and T/NK cells compared to mutations. In T/NK cells, + mutations showed a higher expression of features related to cell activity and differentiation, whereas mutations showed the opposite.

Conclusion: Our research indicates a close association between mutation types and tumor microenvironment in NSCLC, offering insights into personalized approaches for cancer diagnosis and treatment.

References
1.
Laughney A, Hu J, Campbell N, Bakhoum S, Setty M, Lavallee V . Regenerative lineages and immune-mediated pruning in lung cancer metastasis. Nat Med. 2020; 26(2):259-269. PMC: 7021003. DOI: 10.1038/s41591-019-0750-6. View

2.
Leiter A, Veluswamy R, Wisnivesky J . The global burden of lung cancer: current status and future trends. Nat Rev Clin Oncol. 2023; 20(9):624-639. DOI: 10.1038/s41571-023-00798-3. View

3.
Blakely C, Watkins T, Wu W, Gini B, Chabon J, McCoach C . Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers. Nat Genet. 2017; 49(12):1693-1704. PMC: 5709185. DOI: 10.1038/ng.3990. View

4.
Abdulla S, Aevermann B, Assis P, Badajoz S, Bell S, Bezzi E . CZ CELLxGENE Discover: a single-cell data platform for scalable exploration, analysis and modeling of aggregated data. Nucleic Acids Res. 2024; 53(D1):D886-D900. PMC: 11701654. DOI: 10.1093/nar/gkae1142. View

5.
Yan X, Zhao L, Wu F, Shen B, Zhou G, Feng J . Efficacy and safety analysis of immune checkpoint inhibitor rechallenge therapy in locally advanced and advanced non-small cell lung cancer: a retrospective study. J Thorac Dis. 2024; 16(3):1787-1803. PMC: 11009570. DOI: 10.21037/jtd-23-1767. View